Heart Failure, Left Bundle Branch Pacing
Conditions
Keywords
Heart Failure, Left Bundle Branch Pacing, Guideline-Directed Medical Therapy
Brief summary
This is a two-center, prospective randomized controlled trial. The aim of this study is to compare the clinical efficacy of early left bundle branch pacing for cardiac resynchronization therapy and guideline-directed medical therapy in heart failure with mild-reduced ejection fraction.
Detailed description
Early-resync is a two-center, prospective randomized controlled trial that is designed to determine whether early left bundle branch pacing has a better impact on LV function improvement as compared with traditional guideline-directed medical therapy in heart failure with mild-reduced ejection fraction（36%≤LVEF≤50%） and complete left bundle branch block (CLBBB). Patients with symptomatic heart failure,36%≤LVEF≤50%, NYHA function class II-IV, and CLBBB（according to STRAUSS criteria) will be 1:1 randomized to LBBP+GDMT or GDMT group after enrollment and be followed at 3 and 6 months after randomization. LBBP will be performed by a double-chamber device in LBBP+GDMT group. All patients will receive GDMT. The primary endpoint is the change in the LVEF at 6 months after randomization from baseline.
Interventions
DEVICELBBP+GDMT
LBBP is a procedure that the pacing lead is placed at the left bundle branch to achieve electrical and mechanical synchronization by pacing the left bundle branch area with stable pacing parameters.
DRUGGDMT
GDMT is defined as the drug strategy for treatment of heart failure according to the current guidelines.
Sponsors
Fu Wai Hospital, Beijing, China
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
1:1 randomized to two groups
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years; 2. symptomatic heart failure despite guideline-directed medical therapy for at least 3 months, NYHA class II-IV, with an EF between 35% and 50%; 3. complete LBBB meeting Strauss's standard definition 4. Signed informed consent.
Exclusion criteria
1. Expected survival less than 24 months; 2. Indicated for ICD or pacing therapy; 3. History of VT, VF, or hemodynamic instability; 4. History of mechanical tricuspid valve replacement; 5. Ischemic cardiomyopathy scheduled for CABG and PCI within 3 months; 6. Severe structural heart disease may necessitate cardiac surgery or heart transplantation within 1 year; 7. Pregnancy or planning for pregnancy; 8. Hypertrophic cardiomyopathy or those underwent ventricular septal defect repair, in whom the success of LBBP is anticipated to be challenging; 9. Severe renal dysfunction (eGFR \< 15ml/min\*1.73m\^2).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ΔLVEF between baseline and 6-month follow-up | 6 months | ΔLVEF：change in LVEF in percentage (%) between baseline and 6-month follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ΔLVEDD and ΔLVESV between baseline and 6-month follow-up | 6 months | ΔLVEDD：change in LVEDD in millimeters between baseline and 6-month follow-up between two groups. ΔLVESV：change in LVESV in milliliters between baseline and 6-month follow-up between two groups. |
| The echocardiographic response rate of LVEF ≥50% | 6 months | the percentage of patients with LVEF ≥50% at 6 month follow-up |
| The changes of NYHA function class between baseline and 6-month follow-up. | 6 months | NYHA function class (from I to IV) is evaluated by clinicians at each outpatient follow-up visit; |
| Composite incidence rate of all-cause mortality and/or hospitalization for heart failure | 6 months | All-cause death: including cardiovascular and non-cardiovascular deaths. Hospitalization for heart failure: an unplanned outpatient or emergency department visit or inpatient hospitalization in which the patient presented with signs and symptoms consistent with heart failure and required medication therapy. |
| The rate of LVEF <=35% at six-month | 6 months | The percentage of patients with LVEF \<=35% at 6 month follow-up |
| The changes of NT-proBNP between baseline and 6-month follow-up. | 6 months | NT-proBNP in pg/ml was measured by performing a blood test; |
| The changes of 6MWD between baseline and 6-month follow-up. | 6 months | 6MWD in meters stands for "6-Minute Walk Distance." It is a common test used to assess a person's functional exercise capacity and cardiovascular endurance. During the test, the patient is asked to walk as far as possible within a span of 6 minutes in a straight path or designated walking course; |
| The changes of QoL between baseline and 6-month follow-up. | 6 months | QoL stands for "Quality of Life", which is measured by The Minnesota Living with Heart Failure Questionnaire (MLHFQ). The MLHFQ is a self-administered disease-specific questionnaire for patients with HF, comprising 21 items from 0 (none) to 5 (very much). It provides a total score (range 0-105, from best to worst HRQoL). |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORXiaohan Fan, PhD
Chinese Academy of Medical Sciences, Fuwai Hospital
Outcome results
None listed